Trials / Completed
CompletedNCT04975438
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1070806 | GSK1070806 will be administered |
| DRUG | Placebo | Placebo will be administered |
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2022-12-19
- Completion
- 2023-03-13
- First posted
- 2021-07-23
- Last updated
- 2025-08-28
- Results posted
- 2024-07-23
Locations
11 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04975438. Inclusion in this directory is not an endorsement.